Storia in 3 fonti

What's Going On With Celcuity Stock On Tuesday? - Celcuity (NASDAQ:CELC)

Celcuity reported Phase 3 data showing gedatolisib improved progression-free survival in PIK3CA-mutated breast cancer.

Raccontata da

biopharmadive.com

endpoints.news

benzinga.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 mesi fa

What's Going On With Celcuity Stock On Tuesday? - Celcuity (NASDAQ:CELC)

Celcuity reported Phase 3 data showing gedatolisib improved progression-free survival in PIK3CA-mutated breast cancer.

originale

biopharmadive.com1 mesi fa

Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial

Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.

Leggi questa versione → originale

endpoints.news1 mesi fa

Celcuity aims for broad FDA approval after positive breast cancer readout

Celcuity's gedatolisib doubled progression-free survival versus Novartis' Piqray in late-stage breast cancer, setting up a third-quarter FDA submission.

Leggi questa versione → originale

Timeline cronologica

martedì 2 giugno 2026·biopharmadive.com
Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.
martedì 2 giugno 2026·endpoints.news
Celcuity aims for broad FDA approval after positive breast cancer readout
Celcuity's gedatolisib doubled progression-free survival versus Novartis' Piqray in late-stage breast cancer, setting up a third-quarter FDA submission.
martedì 2 giugno 2026·benzinga.com
What's Going On With Celcuity Stock On Tuesday? - Celcuity (NASDAQ:CELC)
Celcuity reported Phase 3 data showing gedatolisib improved progression-free survival in PIK3CA-mutated breast cancer.